A comparison of 4 radionuclides conjugated to antibodies for single-cell kill

Journal of Nuclear Medicine

Volumn 44, Issue 4, 2003, Pages 632-640

  Michel, Rosana B ^a   Brechbiel, Martin W ^b   Mattes, M Jules ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Auger electrons; CD20; Major histocompatibility complex class II; Micrometastases; Radioimmunotherapy

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; ACETIC ACID DERIVATIVE; ANTIBODY; ANTIBODY CONJUGATE; ANTIGEN; BENZYLDIETHYLENETRIAMINEPENTAACETIC ACID; CD20 ANTIBODY; CD74 ANTIBODY; CHELATING AGENT; GALLIUM 67; INDIUM 111; IODINE 125; IODINE 131; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RADIOISOTOPE; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; GALLIUM; INDIUM; LEUKOCYTE ANTIGEN; RADIOACTIVE IODINE; TUMOR ANTIGEN;

ANTIGEN ANTIBODY REACTION; ARTICLE; ASSAY; CALCULATION; CELL KILLING; CELL SURVIVAL; CLINICAL OBSERVATION; CLONOGENIC ASSAY; COMPARATIVE STUDY; DENSITY; DOSIMETRY; DRUG POTENCY; INCUBATION TIME; IODINATION; ISOTOPE LABELING; LYMPHOMA CELL; PRIORITY JOURNAL; RADIOACTIVITY; TARGET CELL; TOXICITY; B CELL LYMPHOMA; CELL COUNT; CELL CULTURE; ELECTRON; EVALUATION; HUMAN; IMMUNOLOGY; METHODOLOGY; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; CELL COUNT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRONS; GALLIUM RADIOISOTOPES; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0038315411     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Govindan SV, Goldenberg DM, Elsamra SE, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with β-particle emitters J Nucl Med. 2000;41:2089-2097
2. Ong GL, Elsamra SE, Goldenberg DM, Mattes MJ. Single-cell cytotoxicity with radiolabeled antibodies. Clin Cancer Res. 2001;7:192-201.
3. 90Y. Clin Cancer Res. 2001;7:1505-1510.
4. Hansen HJ, Ong GL, Diril H, et al Internalization and catabolism of radiolabeled antibodies to the MHC class II invariant chain by B-cell lymphomas Biochem J. 1996;320:293-300.
5. Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells Clin Cancer Res 2002;8:2701-2713.
6. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer. 1997;80:2706-2711.
7. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-BI antibody for B-cell lymphoma: an update on the Michigan phase 1 experience. J Nucl Med. 1998;39(suppl):21S-27S.
8. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002;43:267-272
9. Griffiths GL, Govindan SV, Sgouros G, Ong GL, Goldenberg DM, Mattes MJ. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. Int J Cancer. 1999;81:985-992.
10. Goddu SM, Howell RW, Bouchet LG, Bolch WE, Rao DV. MIRD Cellular S Values. Reston. VA: Society of Nuclear Medicine; 1997
11. Ong GL, Mattes MJ. Processing of antibodies to the MHC class II antigen by B-cell lymphomas release of Fab-like fragments into the medium. Mol Immunol. 1999;36:777-788.
12. Vangeepuram N, Ong GL, Mattes MJ. Processing of antibodies bound to B-cell lymphomas and lymphoblastoid cell lines. Cancer 1997;80(suppl):2425-2430.
13. Little JB, Williams JR Effects of ionizing radiation on mammalian cells In: Lee DHK, Falk HL, Murphy SD, Geiger SR, eds. Handbook of Physiology: Section 9. Bethesda, MD: American Physiological Society, 1977:127-155.
14. Michel RB, Ochakovskaya R, Mattes MJ. Rapid blood clearance of injected mouse IgG2a in SCID mice. Cancer Immunol Immunother. 2002;51:547-556.
15. 125I-labeled monoclonal antibody 17-1a in human cancer cells. Cancer Res. 1989;49:2952-2958.
16. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor Cancer Res. 1992;52:121-126.
17. Daghighian F, Barendswaard E, Welt S, et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med. 1996;37:1052-1057.
18. 131I-labeled CO17-IA in a human colorectal cancer model. Int J Cancer 1998;76:738-748
19. Howell RW. Radiation spectra for Auger-electron emitting radionuclides: report no. 2 of AAPM nuclear medicine task group no. 6 Med Phys. 1992;19:1371-1383.
20. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro comparison of nine radiolabels. J Nucl Med. 1994;35:899-908.
21. Hall EJ. Radiation dose-rate: a factor of importance in radiobiology and radiotherapy Br J Radiol. 1972;45:81-97.
22. Rao DV, Narra VR, Howell RW, Lanka V, Sastry KSR Induction of sperm head abnormalities by incorporated radionuclides, dependence on subcellular distribution, type of radiation, dose rate, and presence of radioprotectors. Radiat Res 1991;125:89-97.
23. Sastry KSR Biological effects of the Auger emitter iodine-125: a review. Med Phys. 1992;19:1361-1370.
24. Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 2002;94:1215-1223